Seek Returns logo

PFE vs. RGC: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at PFE and RGC, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolPFERGC
Company NamePfizer Inc.Regencell Bioscience Holdings Limited
CountryUnited StatesHong Kong
GICS SectorHealth CareHealth Care
GICS IndustryPharmaceuticalsPharmaceuticals
Market Capitalization142.93 billion USD6.07 billion USD
ExchangeNYSENasdaqCM
Listing DateJune 1, 1972July 16, 2021
Security TypeCommon StockCommon Stock

Historical Performance

This chart compares the performance of PFE and RGC by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

PFE vs. RGC: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolPFERGC
5-Day Price Return-0.71%-3.94%
13-Week Price Return9.11%17.22%
26-Week Price Return-2.90%12,700.00%
52-Week Price Return-12.65%5,995.24%
Month-to-Date Return7.94%-3.03%
Year-to-Date Return-5.24%9,746.15%
10-Day Avg. Volume34.56M0.19M
3-Month Avg. Volume42.66M2.18M
3-Month Volatility23.76%642.38%
Beta0.512.33

Profitability

Return on Equity (TTM)

PFE

11.96%

Pharmaceuticals Industry

Max
38.59%
Q3
19.84%
Median
11.90%
Q1
5.63%
Min
-9.96%

PFE’s Return on Equity of 11.96% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.

RGC

-54.75%

Pharmaceuticals Industry

Max
38.59%
Q3
19.84%
Median
11.90%
Q1
5.63%
Min
-9.96%

RGC has a negative Return on Equity of -54.75%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

PFE vs. RGC: A comparison of their Return on Equity (TTM) against the Pharmaceuticals industry benchmark.

Net Profit Margin (TTM)

PFE

16.85%

Pharmaceuticals Industry

Max
34.51%
Q3
17.73%
Median
12.12%
Q1
5.99%
Min
-7.73%

PFE’s Net Profit Margin of 16.85% is aligned with the median group of its peers in the Pharmaceuticals industry. This indicates its ability to convert revenue into profit is typical for the sector.

RGC

--

Pharmaceuticals Industry

Max
34.51%
Q3
17.73%
Median
12.12%
Q1
5.99%
Min
-7.73%

Net Profit Margin data for RGC is currently unavailable.

PFE vs. RGC: A comparison of their Net Profit Margin (TTM) against the Pharmaceuticals industry benchmark.

Operating Profit Margin (TTM)

PFE

18.62%

Pharmaceuticals Industry

Max
41.53%
Q3
23.00%
Median
16.24%
Q1
9.24%
Min
-6.94%

PFE’s Operating Profit Margin of 18.62% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.

RGC

--

Pharmaceuticals Industry

Max
41.53%
Q3
23.00%
Median
16.24%
Q1
9.24%
Min
-6.94%

Operating Profit Margin data for RGC is currently unavailable.

PFE vs. RGC: A comparison of their Operating Profit Margin (TTM) against the Pharmaceuticals industry benchmark.

Profitability at a Glance

SymbolPFERGC
Return on Equity (TTM)11.96%-54.75%
Return on Assets (TTM)5.08%-51.38%
Net Profit Margin (TTM)16.85%--
Operating Profit Margin (TTM)18.62%--
Gross Profit Margin (TTM)73.96%--

Financial Strength

Current Ratio (MRQ)

PFE

1.16

Pharmaceuticals Industry

Max
4.49
Q3
2.77
Median
1.74
Q1
1.26
Min
0.11

PFE’s Current Ratio of 1.16 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

RGC

42.68

Pharmaceuticals Industry

Max
4.49
Q3
2.77
Median
1.74
Q1
1.26
Min
0.11

RGC’s Current Ratio of 42.68 is exceptionally high, placing it well outside the typical range for the Pharmaceuticals industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.

PFE vs. RGC: A comparison of their Current Ratio (MRQ) against the Pharmaceuticals industry benchmark.

Debt-to-Equity Ratio (MRQ)

PFE

0.70

Pharmaceuticals Industry

Max
2.44
Q3
1.07
Median
0.42
Q1
0.11
Min
0.00

PFE’s Debt-to-Equity Ratio of 0.70 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

RGC

0.00

Pharmaceuticals Industry

Max
2.44
Q3
1.07
Median
0.42
Q1
0.11
Min
0.00

Falling into the lower quartile for the Pharmaceuticals industry, RGC’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.

PFE vs. RGC: A comparison of their Debt-to-Equity Ratio (MRQ) against the Pharmaceuticals industry benchmark.

Interest Coverage Ratio (TTM)

PFE

7.89

Pharmaceuticals Industry

Max
103.95
Q3
44.18
Median
9.83
Q1
2.82
Min
-42.71

PFE’s Interest Coverage Ratio of 7.89 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.

RGC

--

Pharmaceuticals Industry

Max
103.95
Q3
44.18
Median
9.83
Q1
2.82
Min
-42.71

Interest Coverage Ratio data for RGC is currently unavailable.

PFE vs. RGC: A comparison of their Interest Coverage Ratio (TTM) against the Pharmaceuticals industry benchmark.

Financial Strength at a Glance

SymbolPFERGC
Current Ratio (MRQ)1.1642.68
Quick Ratio (MRQ)0.8541.89
Debt-to-Equity Ratio (MRQ)0.700.00
Interest Coverage Ratio (TTM)7.89--

Growth

Revenue Growth

PFE vs. RGC: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

PFE vs. RGC: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

PFE

6.65%

Pharmaceuticals Industry

Max
6.98%
Q3
3.32%
Median
2.13%
Q1
0.14%
Min
0.00%

With a Dividend Yield of 6.65%, PFE offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.

RGC

0.00%

Pharmaceuticals Industry

Max
6.98%
Q3
3.32%
Median
2.13%
Q1
0.14%
Min
0.00%

RGC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

PFE vs. RGC: A comparison of their Dividend Yield (TTM) against the Pharmaceuticals industry benchmark.

Dividend Payout Ratio (TTM)

PFE

89.67%

Pharmaceuticals Industry

Max
165.20%
Q3
90.59%
Median
49.13%
Q1
28.91%
Min
0.00%

PFE’s Dividend Payout Ratio of 89.67% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

RGC

0.00%

Pharmaceuticals Industry

Max
165.20%
Q3
90.59%
Median
49.13%
Q1
28.91%
Min
0.00%

RGC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

PFE vs. RGC: A comparison of their Dividend Payout Ratio (TTM) against the Pharmaceuticals industry benchmark.

Dividend at a Glance

SymbolPFERGC
Dividend Yield (TTM)6.65%0.00%
Dividend Payout Ratio (TTM)89.67%0.00%

Valuation

Price-to-Earnings Ratio (TTM)

PFE

13.48

Pharmaceuticals Industry

Max
42.51
Q3
26.88
Median
19.11
Q1
15.12
Min
0.00

In the lower quartile for the Pharmaceuticals industry, PFE’s P/E Ratio of 13.48 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.

RGC

--

Pharmaceuticals Industry

Max
42.51
Q3
26.88
Median
19.11
Q1
15.12
Min
0.00

P/E Ratio data for RGC is currently unavailable.

PFE vs. RGC: A comparison of their Price-to-Earnings Ratio (TTM) against the Pharmaceuticals industry benchmark.

Price-to-Sales Ratio (TTM)

PFE

2.27

Pharmaceuticals Industry

Max
7.55
Q3
4.54
Median
2.11
Q1
1.52
Min
0.00

PFE’s P/S Ratio of 2.27 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

RGC

--

Pharmaceuticals Industry

Max
7.55
Q3
4.54
Median
2.11
Q1
1.52
Min
0.00

P/S Ratio data for RGC is currently unavailable.

PFE vs. RGC: A comparison of their Price-to-Sales Ratio (TTM) against the Pharmaceuticals industry benchmark.

Price-to-Book Ratio (MRQ)

PFE

1.55

Pharmaceuticals Industry

Max
9.78
Q3
4.96
Median
2.23
Q1
1.46
Min
0.60

PFE’s P/B Ratio of 1.55 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

RGC

9.57

Pharmaceuticals Industry

Max
9.78
Q3
4.96
Median
2.23
Q1
1.46
Min
0.60

RGC’s P/B Ratio of 9.57 is in the upper tier for the Pharmaceuticals industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.

PFE vs. RGC: A comparison of their Price-to-Book Ratio (MRQ) against the Pharmaceuticals industry benchmark.

Valuation at a Glance

SymbolPFERGC
Price-to-Earnings Ratio (TTM)13.48--
Price-to-Sales Ratio (TTM)2.27--
Price-to-Book Ratio (MRQ)1.559.57
Price-to-Free Cash Flow Ratio (TTM)10.63--